It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
Gilead’s high profile STELLAR-4 study of its top late-stage NASH drug selonsertib has hit the finish line, and it’s starting out Phase III results with a big-time failure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.